 Proactive Investors USA & Canada | Biogen Idec (BIIB) Shares Given New $127.00 Price Target by Oppenheimer (OPY ... LocalizedUSA It includes BG-12, Daclizumab, Fampridine, GA101, Humanized Anti-CD20 MAb (ocrelizumab), Lixiavaptan, Long-Acting rFactor IX and PEGylated interferon beta-1a. Shares of Biogen Idec traded up 9.40% during mid-day trading on Wednesday, hitting $116.92. ... Analysts rave over Biogen MS pill on second Phase III success Stocks to watch Monday: Mattel, Biogen Idec UPDATE: Piper Jaffray Raises PT on Biogen Idec to $135 |
